2 Stocks to Buy Hand Over Fist if a Stock Market Crash Is Coming

The article identifies Coca-Cola and Johnson & Johnson as recession-resistant dividend stocks, citing each company's 64 consecutive annual dividend increases. Coca-Cola trades at 25.2x forward earnings versus a 21x consumer-staples average, reflecting a premium for its defensive business and income profile. Johnson & Johnson's proposed $5.5 billion ovarian talc litigation settlement, AAA S&P credit rating, diversified pharmaceutical and medical-device portfolio, and resilience to drug-pricing pressure support its safe-haven case.

Analysis

This is not a fresh fundamental catalyst; it reinforces an already crowded quality/defensive positioning trade. KO's premium valuation leaves limited room for multiple expansion unless it demonstrates sustained volume/mix resilience despite a weaker consumer, while its international exposure creates a meaningful offsetting risk from USD strength and emerging-market currency translation. In a risk-off move, KO should outperform the S&P 500, but absolute upside is likely capped by bond-yield sensitivity: a renewed rise in real yields can pressure the stock even if earnings remain stable.

JNJ has the more attractive defensive setup because its earnings drivers are less tied to discretionary consumption and its medical-device franchise can add operating leverage as procedure volumes recover. The key distinction is legal optionality: resolution certainty on talc could remove a persistent valuation discount and reduce balance-sheet tail-risk perception, whereas any failure of the settlement process would likely create a sharper, event-driven drawdown than a conventional recession would. Drug-pricing pressure is a slower 6-18 month margin issue, not an immediate demand shock, and pipeline/readout execution will determine whether replacement products can offset mature-brand erosion.

Contrarian view: investors buying these names solely as recession hedges may be late. If growth merely decelerates rather than contracts, cyclicals and lower-multiple healthcare could outperform expensive defensives; if a recession is severe, the equity-duration component of KO and JNJ still does not immunize them from index-level de-risking. The better expression is relative performance rather than a large outright beta bet.

Key Decisions for Investors

• Initiate a 1-3 month pair trade: long JNJ / short XLP, sized beta-neutral. JNJ offers litigation-resolution and pipeline catalysts absent from the staples ETF, while XLP embeds broad premium-defensive exposure. Reassess if JNJ's talc settlement approval is delayed or if pharma guidance is cut.
• Use KO as a tactical downside hedge only on broad-market weakness: buy KO versus short SPY for a 1-3 month risk-off window rather than chase outright. Exit the relative long if the USD strengthens materially or if KO reports negative global unit-case volume; the valuation premium makes those risks more consequential than a modest earnings miss.
• Avoid adding outright JNJ ahead of a binary legal ruling without defined downside. For investors requiring exposure, use a 6-9 month call spread financed with an out-of-the-money put spread only after confirming settlement-process milestones; upside is discount removal, while the primary falsifier is renewed litigation uncertainty.
• Monitor 10-year real yields and defensive relative performance: if real yields rise while KO/XLP continue outperforming, reduce exposure. That combination signals valuation compression risk outweighing defensive earnings support.